Vincent Cottin
Prof Vincent Cottin is an expert in Pulmonology at Hôpital Louis Pradel (France). As of October 2026, ScienceLeadR ranks Vincent Cottin in the top 1% of experts worldwide for Emphysema, Hypertension and Lung Diseases, Interstitial. Vincent Cottin has authored 1,153 publications, the most recent in 2026, and is an investigator in 79 clinical trials, 18 of them ongoing. SLR score: 5,073 (community average: 125). How the SLR is computed.
LeadR Profile
Pulmonology
Subspecialties: Critical Care - Internal Medicine - Rheumatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 1153
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. PMID 42776606 — idiopathic pulmonary fibrosis, quality of life, lung, fibrosis, critical care, pulmonary fibrosis, vital capacity | Am J Respir Crit Care Med | 2026 | 0 |
| Effect of nerandomilast on survival in patients with pulmonary fibrosis. PMID 42532543 — fibrosis, respiratory tract diseases, respiration, pulmonary fibrosis | Eur Respir J | 2026 | 1 |
| Pulmonary vascular complications following lung transplantation: characteristics, incidence, survival. PMID 42492331 — pulmonary veins, hypertension, lung, hypertension, pulmonary, embolism, incidence, pulmonary embolism, lung diseases, lung transplantation, veins, transplantation | Respir Med Res | 2026 | 0 |
| Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial. PMID 42474242 — exercise, research design, hypertension, safety, respiratory tract diseases, rehabilitation, pulmonary arterial hypertension | Ann Am Thorac Soc | 2026 | 0 |
| Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report. PMID 42447235 — lung, critical care, signs and symptoms, pneumonia, research, therapeutics, lung diseases, lung diseases, interstitial | Am J Respir Crit Care Med | 2026 | 0 |
Clinical Studies 79
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 6
Ongoing Clinical Trials
18 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of Intravenous ABBV 142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis 2024-518013-25-00 — idiopathic pulmonary fibrosis, fibrosis, drug-related side effects and adverse reactions, pulmonary fibrosis, therapeutics | Phase 2 | Not yet recruiting | 2026 |
| A Study to Evaluate the Efficacy Safety and Tolerability of BMS 986278 in Participants with Idiopathic Pulmonary Fibrosis 2023-503697-21-01 — idiopathic pulmonary fibrosis, safety, fibrosis, pulmonary fibrosis, vital capacity | Phase 3 | Active not recruiting | 2024 |
| A Study to Evaluate the Efficacy Safety and Tolerability of BMS 986278 in Participants with Progressive Pulmonary Fibrosis 2023-503699-25-00 — safety, fibrosis, pulmonary fibrosis, vital capacity | Phase 3 | Active not recruiting | 2024 |
| An Open Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent 2024-518289-28-00 — idiopathic pulmonary fibrosis, fibrosis, pulmonary fibrosis | Phase 2 | Not yet recruiting | 2025 |
| A Phase 3 Randomized Double blind Placebo controlled Multicenter Parallel Group Study to Evaluate the Efficacy and Safety of Trepostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease 2025-521558-40-00 — hypertension, lung, hypertension, pulmonary, safety, powders, inhalation, therapeutics, lung diseases, lung diseases, interstitial | Phase 3 | Recruiting | 2026 |
LeadR Networks
Main global connection map